Free Trial

Syros Pharmaceuticals (SYRS) SEC Filings & 10K Form

Syros Pharmaceuticals logo
$0.17 0.00 (-0.85%)
Closing price 02/21/2025 04:00 PM Eastern
Extended Trading
$0.17 0.00 (-1.89%)
As of 02/21/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Syros Pharmaceuticals SEC Filings

DateFilerForm TypeView
02/14/2025
9:10 AM
Avidity Partners Management LP (Filed by)
Syros Pharmaceuticals (Subject)
Form SCHEDULE 13G/A
02/14/2025
7:41 AM
Deep Track Capital, LP (Filed by)
Syros Pharmaceuticals (Subject)
Form SCHEDULE 13G/A
02/12/2025
8:41 AM
ADAGE CAPITAL PARTNERS GP, L.L.C. (Filed by)
Syros Pharmaceuticals (Subject)
Form SCHEDULE 13G/A
01/16/2025
3:49 PM
Flagship Pioneering Fund VII, L.P. (Reporting)
Syros Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/08/2025
3:01 PM
Syros Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/30/2024
4:11 PM
AKKARAJU SRINIVAS (Reporting)
Syros Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/27/2024
3:02 PM
Flagship Pioneering Fund VII, L.P. (Reporting)
Syros Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/13/2024
3:17 PM
Flagship VentureLabs IV, LLC (Reporting)
Syros Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/10/2024
2:01 PM
Syros Pharmaceuticals (Subject)
Young Richard A (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/06/2024
6:00 AM
Syros Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/25/2024
4:59 PM
Simonian Nancy A (Reporting)
Syros Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/19/2024
4:22 PM
Quirk Gerald E (Reporting)
Syros Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/18/2024
4:42 PM
Roth David (Reporting)
Syros Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/18/2024
5:00 PM
Haas Jason (Reporting)
Syros Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/18/2024
4:20 PM
Stephens Kristin (Reporting)
Syros Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/18/2024
3:45 PM
Chee Conley (Reporting)
Syros Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/18/2024
3:18 PM
Haas Jason (Reporting)
Syros Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/18/2024
11:08 AM
Chee Conley (Reporting)
Syros Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/18/2024
6:01 AM
Syros Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/14/2024
4:24 PM
Bain Capital Life Sciences Fund II, L.P. (Filed by)
Syros Pharmaceuticals (Subject)
Form SC 13G/A
11/14/2024
4:28 PM
Avidity Partners Management LP (Filed by)
Syros Pharmaceuticals (Subject)
Form SC 13G/A
11/13/2024
6:00 AM
Syros Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/04/2024
4:00 PM
Stephens Kristin (Reporting)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/04/2024
4:01 PM
Chee Conley (Reporting)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/04/2024
4:01 PM
Haas Jason (Reporting)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/04/2024
4:01 PM
Roth David (Reporting)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/04/2024
4:01 PM
Simonian Nancy A (Reporting)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/31/2024
5:49 AM
Syros Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/02/2024
4:00 PM
Quirk Gerald E (Reporting)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/18/2024
4:00 PM
Syros Pharmaceuticals (Issuer)
Young Richard A (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/18/2024
4:00 PM
AKKARAJU SRINIVAS (Reporting)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/12/2024
4:00 PM
Chee Conley (Reporting)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/12/2024
4:00 PM
Haas Jason (Reporting)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/05/2024
6:01 AM
Syros Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/12/2024
4:03 PM
Syros Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/02/2024
5:39 PM
Invus Global Management, LLC (Filed by)
Syros Pharmaceuticals (Subject)
Form SC 13G/A
07/31/2024
6:44 AM
Syros Pharmaceuticals (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
07/31/2024
5:55 AM
Syros Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
06/07/2024
3:30 PM
Syros Pharmaceuticals (Issuer)
WIRTH PETER (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/07/2024
3:30 PM
AKKARAJU SRINIVAS (Reporting)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/07/2024
3:30 PM
Fanucci Marsha (Reporting)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
How to trade Executive Order 14154 (Ad)

Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orders. Among this blizzard of directives – ranging from slapping 25% tariffs on steel to banning the forced use of paper straws… Everyone seems to have missed the most important detail of all.

Get the true, untold story of what’s hidden inside Executive Order 14154, here.
06/07/2024
3:30 PM
OH ANDREW M. (Reporting)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/07/2024
3:30 PM
Eckhardt Sue Gail (Reporting)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/07/2024
3:30 PM
Dunsire Deborah (Reporting)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/07/2024
3:30 PM
Syros Pharmaceuticals (Issuer)
TYSON TIMOTHY (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/07/2024
3:30 PM
Syros Pharmaceuticals (Issuer)
Young Richard A (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/07/2024
3:30 PM
Simonian Nancy A (Reporting)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/06/2024
3:30 PM
Syros Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/04/2024
3:41 PM
AKKARAJU SRINIVAS (Reporting)
AKKARAJU SRINIVAS (Reporting)
Syros Pharmaceuticals (Issuer)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2024
5:42 AM
Syros Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/23/2024
6:01 AM
Syros Pharmaceuticals (Filer)
Form DEF 14A
04/23/2024
6:05 AM
Syros Pharmaceuticals (Filer)
Form DEFA14A
04/23/2024
6:10 AM
Syros Pharmaceuticals (Filer)
Form ARS
04/12/2024
3:30 PM
Syros Pharmaceuticals (Filer)
Form PRE 14A
04/05/2024
3:30 PM
Roth David (Reporting)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
04/02/2024
3:54 PM
Haas Jason (Reporting)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
04/02/2024
3:57 PM
Quirk Gerald E (Reporting)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
04/02/2024
3:58 PM
Roth David (Reporting)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
04/02/2024
3:59 PM
Simonian Nancy A (Reporting)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
04/02/2024
4:01 PM
Stephens Kristin (Reporting)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
04/02/2024
3:14 PM
Roth David (Reporting)
Syros Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/27/2024
6:04 AM
Syros Pharmaceuticals (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/27/2024
5:49 AM
Syros Pharmaceuticals (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:SYRS) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners